APIMEDS PHARMACEUTICALS US, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $1.67 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-05-04.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-05-04
- APIMEDS PHARMACEUTICALS US, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $1.67K, a 868.02% increase from fiscal 2024.
- APIMEDS PHARMACEUTICALS US, INC. effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2024 was $172.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month |
|---|---|
| 2025-12-31 | $1.67K 10-K · filed 2026-05-04 |
| 2024-12-31 | $172.00 10-K · filed 2026-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |